Drug repurposing for pancreatic cancer: Lomitapide Mesylate as a potent HK2 inhibitor discovered via virtual screening. (PubMed, Cell Signal) - Jun 4, 2026 - "Pancreatic cancer has an early diagnosis rate below 5% and is largely resistant to conventional chemotherapy. Mechanistically, this synergy was linked to LM-mediated reversal of HK2-driven EMT. Thus, LM inhibits HK2 to block EMT and synergize with gemcitabine, offering a novel therapeutic strategy."
Journal • Oncology • Pancreatic Cancer • Solid Tumor • HK2
|
|
Bangwei Huang; Dan Wang; Fan Wang; Jianguo Gao; Lianghao Hu; Libo Liu; Miao Liu; Pengyuan Wang; Xin Tan; Xinyi Yang; Ying Zhang; Yue Wang; Zhaoshen Li; Zijian Si
|